HCC827-Luc Cells

HCC827-Luc is a bioluminescent derivative of the human HCC827 lung adenocarcinoma cell line, engineered to stably express a firefly luciferase reporter gene. The parental HCC827 cell line was established from a lung adenocarcinoma and is notable for harboring an activating EGFR exon 19 deletion (del E746-A750), which confers high sensitivity to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and osimertinib. HCC827 is therefore one of the most widely used preclinical models for studying EGFR-driven lung cancer biology, mechanisms of acquired TKI resistance, and the efficacy of next-generation targeted therapies.

The stable luciferase integration in HCC827-Luc enables sensitive, quantitative bioluminescence imaging (BLI) of tumor burden in xenograft and orthotopic lung tumor models in immunocompromised hosts. The emitted luminescent signal correlates with viable tumor cell number, supporting noninvasive longitudinal monitoring of tumor engraftment, growth kinetics, metastatic dissemination, and therapeutic response. This makes HCC827-Luc particularly suitable for evaluating the efficacy of EGFR-targeted agents, combination therapies, and resistance-reversal strategies in preclinical in vivo settings.

HCC827-Luc retains the key molecular and phenotypic features of the parental HCC827 line, including EGFR exon 19 deletion status and sensitivity to approved EGFR inhibitors. The luciferase modification substantially enhances experimental sensitivity and throughput, enabling real-time pharmacodynamic assessments and facilitating both high-throughput drug screening and mechanistic investigations of EGFR pathway biology. Researchers should verify luciferase activity, EGFR mutation status, and growth kinetics under their specific experimental conditions prior to use in quantitative imaging or pharmacological studies.